Bioventus (NASDAQ:BVS) Releases FY 2026 Earnings Guidance

Bioventus (NASDAQ:BVS) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 0.750-0.790 for the period, compared to the consensus estimate of 0.770. The company issued revenue guidance of $600.0 million-$610.0 million, compared to the consensus revenue estimate of $605.1 million.

Bioventus Trading Down 0.4%

Shares of BVS opened at $13.42 on Wednesday. The company has a current ratio of 1.69, a quick ratio of 1.13 and a debt-to-equity ratio of 1.08. The stock has a market cap of $1.12 billion, a PE ratio of 32.73, a PEG ratio of 1.72 and a beta of 0.63. Bioventus has a 1 year low of $5.81 and a 1 year high of $14.00. The stock has a 50 day simple moving average of $10.47 and a 200-day simple moving average of $9.56.

Bioventus (NASDAQ:BVS) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.22 EPS for the quarter. Bioventus had a return on equity of 29.97% and a net margin of 4.94%.The business had revenue of $153.21 million for the quarter. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. On average, sell-side analysts predict that Bioventus will post 0.79 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on BVS shares. Barrington Research reissued an “outperform” rating and issued a $14.00 target price on shares of Bioventus in a report on Tuesday, June 30th. Canaccord Genuity Group reissued a “buy” rating and issued a $15.00 price objective on shares of Bioventus in a research note on Tuesday, June 16th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Bioventus in a report on Tuesday, June 2nd. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $14.75.

Institutional Investors Weigh In On Bioventus

Large investors have recently bought and sold shares of the company. Corient Private Wealth LLC raised its holdings in Bioventus by 44.9% in the fourth quarter. Corient Private Wealth LLC now owns 19,471 shares of the company’s stock worth $145,000 after purchasing an additional 6,031 shares during the period. Invesco Ltd. grew its holdings in shares of Bioventus by 52.9% in the 4th quarter. Invesco Ltd. now owns 33,621 shares of the company’s stock valued at $250,000 after buying an additional 11,639 shares during the period. Mercer Global Advisors Inc. ADV increased its position in shares of Bioventus by 16.2% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 13,529 shares of the company’s stock valued at $101,000 after buying an additional 1,887 shares in the last quarter. EP Wealth Advisors LLC bought a new stake in shares of Bioventus in the 4th quarter valued at $135,000. Finally, Tudor Investment Corp ET AL bought a new stake in shares of Bioventus in the 4th quarter valued at $347,000. Institutional investors own 62.94% of the company’s stock.

Bioventus Company Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.